News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial


9/26/2012 8:53:07 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced initiation of its Phase 2/3 pivotal trial of EXPAREL® (bupivacaine liposome injectable suspension) administered as a single-dose injection femoral nerve block for total knee arthroplasty surgery. Results from this study and a forthcoming second trial focused on intercostal nerve block for thoracotomy will contribute to a planned U.S. Food and Drug Administration supplemental New Drug Application (sNDA) filing in late 2013 or early 2014.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES